[ad_1]
A new study has found that people who have already contracted COVID-19 exhibit a more potent antibody response than those who have only been vaccinated against the respiratory virus.
Conducted by a research team from Rockefeller University in New York, the analysis revealed “that between a first (first) and a second (booster) vaccine from either Pfizer-BioNTech or Moderna vaccine, the memory B cells of the Infection-naïve individuals produced antibodies. which developed an increased neutralizing activity against SARS-CoV-2 ”, but also that“ no further increase in the potency or extent of this activity was observed thereafter ”.
Meanwhile, the researchers determined that not only do recovered COVID-19 patients possess neutralizing antibodies for up to a year after infection, but that such infection simultaneously helps protect against the development of variants.
“Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) produces B-cell responses that continue to evolve for at least a year,” the study said. “Meanwhile, memory B cells are expressing increasingly large and potent antibodies that resist mutations found in the variants of concern.”
The analysis later concludes: “Memory antibodies selected over time by natural infection have greater potency and magnitude than antibodies induced by vaccination.
In addition, the results suggest that “strengthening of vaccinated individuals with currently available mRNA vaccines would produce a quantitative increase in plasma neutralization activity, but not the qualitative benefit against variants obtained by vaccinating convalescent individuals”.
The study results add to a growing body of evidence detailing the level of protection that natural immunity offers to previously infected COVID-19 patients. Last month, Emory University published an in-depth survey describing the effectiveness of long-term immunity against the respiratory virus. Similar findings were also identified in research published by the Cleveland Clinic and the Washington University School of Medicine in St. Louis, respectively.
Shawn Fleetwood is an intern at The Federalist and a student at the University of Mary Washington, where he plans to major in political science and major in journalism. He is also a state content writer for the Convention of States Action. Follow him on Twitter @ShawnFleetwood
[ad_2]
Source link